About ImmuCell (NASDAQ:ICCC)
ImmuCell Corporation develops, acquires, manufactures, and sells products that enhance animal health and productivity of cows for the dairy and beef industries in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; Wipe Out Dairy Wipes, which consist of towelettes that are pre-moistened with a Nisin-based formulation to prepare the teat area of a cow in advance of milking; and California Mastitis Test that could be used for bulk tank and individual cow sample monitoring, as well as to determine which quarter of the udder is mastitic. It is also involved in the development of Mast Out, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and treatments that prevent E. coli K99 and bovine coronavirus, as well as calf scours caused by enteric pathogens. In addition, the company sells various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to distributors and bovine veterinarians, as well as directly to producers. The company was founded in 1982 and is based in Portland, Maine.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ICCC
CUSIPN/A
Phone207-878-2770
Debt
Debt-to-Equity Ratio0.37%
Current Ratio3.64%
Quick Ratio2.65%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$10.43 million
Price / Sales3.74
Cash Flow$0.1312 per share
Price / Cash54.20
Book Value$4.31 per share
Price / Book1.65
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-160,000.00
Net Margins-1.61%
Return on Equity-0.79%
Return on Assets-0.57%
Miscellaneous
Employees47
Outstanding Shares5,480,000
ImmuCell (NASDAQ:ICCC) Frequently Asked Questions
What is ImmuCell's stock symbol?
ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."
How were ImmuCell's earnings last quarter?
ImmuCell Co. (NASDAQ:ICCC) posted its earnings results on Thursday, February, 8th. The biotechnology company reported ($0.04) EPS for the quarter. The biotechnology company earned $3.13 million during the quarter. ImmuCell had a negative return on equity of 0.79% and a negative net margin of 1.61%. View ImmuCell's Earnings History.
When is ImmuCell's next earnings date?
Who are some of ImmuCell's key competitors?
Some companies that are related to ImmuCell include Trinity Biotech (TRIB), AspenBio Pharma (RIOT), Celldex Therapeutics (CLDX), Vermillion (VRML), Akers Biosciences (AKER), Achieve Life Sciences (ACHV), Genenews (GNWSF), ARCA biopharma (ABIO), FluoroPharma Medical (FPMI), BG Medicine (BGMD), Response Genetics (RGDXQ) and Palatin Technologies (PTN).
Who are ImmuCell's key executives?
ImmuCell's management team includes the folowing people:
- Mr. Michael F. Brigham, Chief Exec. Officer, Pres, Chief Financial Officer, Treasurer, Sec. and Director (Age 57)
- Dr. Joseph H. Crabb Ph.D., Chief Scientific Officer & VP (Age 63)
- Ms. Bobbi Jo Brockmann, VP of Sales & Marketing and Director (Age 41)
- Ms. Elizabeth L. Williams, VP of Manufacturing Operations (Age 62)
Has ImmuCell been receiving favorable news coverage?
News coverage about ICCC stock has been trending somewhat positive on Thursday, according to Accern. The research firm rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ImmuCell earned a media sentiment score of 0.13 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 46.01 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of ImmuCell?
Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ImmuCell's stock price today?
One share of ICCC stock can currently be purchased for approximately $7.11.
How big of a company is ImmuCell?
ImmuCell has a market capitalization of $39.70 million and generates $10.43 million in revenue each year. ImmuCell employs 47 workers across the globe.
How can I contact ImmuCell?
ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]
MarketBeat Community Rating for ImmuCell (ICCC)
MarketBeat's community ratings are surveys of what our community members think about ImmuCell and other stocks. Vote "Outperform" if you believe ICCC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICCC will underperform the S&P 500 over the long term. You may vote once every thirty days.
ImmuCell (NASDAQ:ICCC) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
(Data available from 4/26/2016 forward)
ImmuCell (NASDAQ:ICCC) Earnings History and Estimates Chart
ImmuCell (NASDAQ ICCC) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/10/2018 | | | | | | | | |
| 2/8/2018 | Q4 2017 | | ($0.04) | | $3.13 million | View | Listen |  |
| 11/13/2017 | Q3 2017 | | ($0.07) | | $2.01 million | View | N/A | |
| 8/14/2017 | Q2 2017 | | ($0.05) | | $1.75 million | View | N/A | |
| 5/11/2017 | Q1 2017 | | $0.12 | | $3.54 million | View | N/A | |
| 2/9/2017 | Q416 | | $0.01 | $2.70 million | $2.20 million | View | Listen | |
| 11/10/2016 | Q316 | | $0.01 | $1.61 million | $1.97 million | View | N/A | |
| 5/11/2016 | Q1 | | $0.11 | | $2.99 million | View | N/A | |
| 2/10/2016 | Q315 | | $0.09 | $2.21 million | $2.70 million | View | Listen | |
| 11/12/2015 | Q3 | | $0.11 | | $2.47 million | View | Listen | |
| 8/13/2015 | Q215 | | $0.03 | $1.54 million | $1.96 million | View | N/A | |
| 5/12/2015 | Q1 2015 | | $0.15 | | $3.10 million | View | N/A | |
| 2/11/2015 | Q414 | | $0.04 | $1.56 million | $2.21 million | View | N/A | |
| 8/12/2014 | Q214 | | ($0.10) | $1.37 million | $1.54 million | View | N/A | |
| 2/13/2014 | Q413 | | ($0.05) | $1.42 million | $1.56 million | View | N/A | |
| 11/12/2013 | Q313 | | $0.02 | $1.08 million | $1.24 million | View | N/A | |
| 5/14/2013 | Q1 2013 | | $0.07 | | $1.85 million | View | N/A | |
| 2/14/2013 | Q4 2012 | | ($0.01) | | | View | N/A | |
| 11/7/2012 | Q312 | | ($0.02) | $1.00 million | $1.08 million | View | N/A | |
| 5/14/2012 | Q1 2012 | | $0.05 | | | View | N/A | |
| 11/14/2011 | Q3 2011 | | ($0.04) | | | View | N/A | |
| 8/15/2011 | Q2 2011 | | ($0.09) | | | View | N/A | |
| 5/16/2011 | Q1 2011 | | $0.01 | | | View | N/A | |
| 2/9/2011 | Q4 2010 | | $0.04 | | | View | N/A | |
| 11/8/2010 | Q3 2010 | | ($0.07) | | | View | N/A | |
| 5/6/2010 | Q1 2010 | | ($0.02) | | | View | N/A | |
| 2/10/2010 | Q4 2009 | | ($0.01) | | | View | N/A | |
| 11/4/2009 | Q3 2009 | | ($0.01) | | | View | N/A | |
| 8/4/2009 | Q2 2009 | | ($0.05) | | | View | N/A | |
| 5/5/2009 | Q1 2009 | | ($0.01) | | | View | N/A | |
| 2/11/2009 | Q4 2008 | | ($0.01) | | | View | N/A | |
| 11/4/2008 | Q3 2008 | | ($0.09) | | | View | N/A | |
| 8/4/2008 | Q2 2008 | | ($0.08) | | | View | N/A | |
| 5/5/2008 | Q1 2008 | | $0.03 | | | View | N/A | |
| 2/7/2008 | Q4 2007 | | $0.02 | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
ImmuCell (NASDAQ:ICCC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
ImmuCell (NASDAQ ICCC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 20.10%
Institutional Ownership Percentage: 12.42%
ImmuCell (NASDAQ ICCC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 7/27/2017 | Brian L Pessin | Insider | Buy | 30,000 | $5.25 | $157,500.00 | 70,000 | |
| 3/14/2017 | David Scott Tomsche | Director | Buy | 2,000 | $5.43 | $10,860.00 | 71,279 | |
| 11/7/2016 | David Scott Tomsche | Director | Buy | 4,000 | $5.19 | $20,760.00 | | |
| 7/8/2016 | Joseph H Crabb | VP | Sell | 1,935 | $6.55 | $12,674.25 | 106,705 | |
| 7/7/2016 | Joseph H Crabb | VP | Sell | 2,691 | $6.58 | $17,706.78 | 108,837 | |
| 7/5/2016 | Joseph H Crabb | VP | Sell | 5,374 | $6.74 | $36,220.76 | 115,037 | |
| 3/21/2016 | David Scott Tomsche | Director | Buy | 955 | $6.67 | $6,369.85 | 66,789 | |
| 1/29/2016 | David Cunningham | Director | Buy | 1,904 | $5.25 | $9,996.00 | 7,404 | |
| 9/3/2015 | Jonathan E. Rothschild | Director | Buy | 3,000 | $6.63 | $19,890.00 | 524,636 | |
| 9/1/2015 | David Scott Tomsche | Director | Buy | 1,000 | $6.73 | $6,730.00 | 59,168 | |
| 8/31/2015 | Jonathan E. Rothschild | Director | Buy | 6,100 | $7.37 | $44,957.00 | 521,636 | |
| 8/28/2015 | David Scott Tomsche | Director | Buy | 1,500 | $7.27 | $10,905.00 | 58,168 | |
| 11/26/2014 | Jonathan E Rothschild | Director | Buy | 2,100 | $4.82 | $10,122.00 | | |
| 8/20/2014 | Jonathan E Rothschild | Director | Buy | 3,000 | $4.55 | $13,650.00 | | |
| 6/16/2014 | Jonathan E Rothschild | Director | Buy | 5,901 | $4.57 | $26,967.57 | | |
| 5/15/2014 | David Cunningham | Director | Buy | 1,500 | $3.91 | $5,865.00 | | |
| 8/23/2013 | Jonathan E Rothschild | Director | Buy | 1,500 | $3.98 | $5,970.00 | | |
| 8/16/2013 | David Cunningham | Director | Buy | 4,000 | $3.68 | $14,720.00 | | |
(Data available from 1/1/2013 forward)
ImmuCell (NASDAQ ICCC) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Who Are The Largest Shareholders In ImmuCell Corporation (NASDAQ:ICCC)?
finance.yahoo.com - April 11 at 4:19 PM |
 | ImmuCell (ICCC) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - April 6 at 1:55 PM |
| Where ImmuCell Corporation (NASDAQ:ICCC) Stands In Terms Of Earnings Growth Against Its Industry
finance.yahoo.com - March 6 at 9:32 AM |
| ImmuCell (ICCC) Posts Quarterly Earnings Results
www.americanbankingnews.com - February 9 at 12:23 PM |
| ImmuCell Corporation to Host Earnings Call
finance.yahoo.com - February 8 at 4:31 PM |
| ImmuCell Announces Preliminary Financial Results for Fourth Quarter and Full Year 2017
finance.yahoo.com - February 8 at 4:31 PM |
| ImmuCell to Announce Financial Results for Fourth Quarter and Full Year 2017
finance.yahoo.com - February 6 at 8:59 AM |
| ImmuCell Appoints Two New Members to its Board of Directors
finance.yahoo.com - January 30 at 9:22 AM |
| ImmuCell Corp. :ICCC-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 5:00 PM |
| ImmuCell Corporation Announces Closing of $3 Million Public Offering of Common Stock
finance.yahoo.com - December 21 at 4:09 PM |
 | Immucell Corp (ICCC) Prices $3M Public Offering of Common Shares
www.streetinsider.com - December 19 at 10:55 AM |
| ImmuCell Corporation (ICCC) Releases Earnings Results
www.americanbankingnews.com - November 14 at 9:56 AM |
| Edited Transcript of ICCC earnings conference call or presentation 13-Nov-17 9:30pm GMT
finance.yahoo.com - November 14 at 5:47 AM |
 | ImmuCell Corp's (ICCC) CEO Michael Brigham on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 14 at 12:46 AM |
| Immucell Corp (ICCC) Announces USDA Approval of New Product Claim to Prevent Rotavirus Infections
www.streetinsider.com - November 13 at 7:46 PM |
| ImmuCell Achieves USDA Approval of New Product Claim to Prevent Rotavirus Infections
finance.yahoo.com - November 13 at 7:46 PM |
| ImmuCell Announces Financial Results for Third Quarter of 2017
finance.yahoo.com - November 13 at 7:46 PM |
| ImmuCell Announces Completion of Construction of Nisin Production Facility
finance.yahoo.com - November 8 at 10:04 AM |
| ImmuCell Corporation (ICCC) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - November 6 at 12:17 PM |
| ImmuCell to Announce Financial Results for Third Quarter of 2017
finance.yahoo.com - November 3 at 8:51 AM |
| ImmuCell Corp. :ICCC-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 8:12 PM |
| Did ImmuCell Corporation (ICCC) Create Value For Investors Over The Past Year?
finance.yahoo.com - October 5 at 10:47 AM |
| ImmuCell Announces Expansion of Sales and Marketing Team
finance.yahoo.com - September 14 at 6:18 AM |
| ImmuCell Corp's (ICCC) CEO Michael Brigham on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 15 at 11:55 PM |
| Edited Transcript of ICCC earnings conference call or presentation 14-Aug-17 8:30pm GMT
finance.yahoo.com - August 15 at 11:55 PM |
| Investor Network: ImmuCell Corporation to Host Earnings Call
finance.yahoo.com - August 14 at 10:03 PM |
| ImmuCell Announces Financial Results for Second Quarter of 2017
finance.yahoo.com - August 14 at 10:03 PM |
| ImmuCell Co. (NASDAQ:ICCC) Announces Quarterly Earnings Results
www.americanbankingnews.com - August 14 at 8:22 PM |
| ImmuCell to Announce Financial Results for Second Quarter of 2017
finance.yahoo.com - August 7 at 7:11 PM |
| Insider Buying: ImmuCell Corporation (ICCC) Insider Buys 30,000 Shares of Stock
www.americanbankingnews.com - July 28 at 7:35 PM |
| ImmuCell Closes $1,000,000 Equity Investment
finance.yahoo.com - July 27 at 10:14 PM |
| ImmuCell Unveils New Website
finance.yahoo.com - July 17 at 3:42 PM |
| ImmuCell Clarifies Number of Authorized Common Shares
finance.yahoo.com - July 14 at 3:18 AM |
| IMMUCELL CORP /DE/ Files SEC form 10-K, Annual Report
biz.yahoo.com - March 30 at 6:12 PM |
| IMMUCELL CORP /DE/ Files SEC form 8-K, Change in Directors or Principal Officers, Entry into a Material Definitive Ag
biz.yahoo.com - March 8 at 6:36 PM |
| IMMUCELL CORP /DE/ Files SEC form 8-K, Other Events
biz.yahoo.com - March 2 at 6:11 PM |
| ImmuCell Corporation (ICCC)
seekingalpha.com - February 11 at 5:53 PM |
| IMMUCELL CORP /DE/ Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - February 10 at 6:34 PM |
| Q4 2016 ImmuCell Corp Earnings Release - After Market Close
biz.yahoo.com - February 9 at 6:43 PM |
| ImmuCell's (ICCC) CEO Michael Brigham on Q3 2016 Results - Earnings Call Transcript
seekingalpha.com - November 12 at 8:02 AM |
| Immucell Corp (ICCC) Reports Q3 EPS of $0.01
www.streetinsider.com - November 12 at 8:02 AM |
| IMMUCELL CORP /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - October 21 at 5:39 PM |
| Immucell Corp (ICCC) Offers Prelim. Q3 Results; Says Sales Fell 20%
www.streetinsider.com - October 19 at 10:27 AM |
| ImmuCell Announces Preliminary Third Quarter 2016 Financial Results
www.streetinsider.com - October 18 at 10:37 AM |
 | ImmuCell to Raise $3.5 Million in Private Placement
www.marketwatch.com - October 18 at 10:37 AM |
| IMMUCELL CORP /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - October 18 at 10:37 AM |
 | ImmuCell Announces Second Quarter 2016 Financial Results
www.finanznachrichten.de - August 13 at 8:31 AM |
| ImmuCell's (ICCC) CEO Michael Brigham on Q2 2016 Results - Earnings Call Transcript
seekingalpha.com - August 13 at 8:31 AM |
| Immucell Corp (ICCC) Reports Q2 EPS of $0.00
www.streetinsider.com - August 13 at 8:31 AM |
| Q2 2016 ImmuCell Corp Earnings Release - After Market Close
biz.yahoo.com - August 11 at 8:36 AM |
ImmuCell (NASDAQ:ICCC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
ImmuCell (NASDAQ:ICCC) Income Statement, Balance Sheet and Cash Flow Statement
ImmuCell (NASDAQ ICCC) Stock Chart for Thursday, April, 26, 2018
Loading chart…
